Skip to main content
Top
Published in: Neurology and Therapy 4/2022

Open Access 29-07-2022 | Antipsychotics | Original Research

Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel

Authors: Rajesh Pahwa, Stuart H. Isaacson, Gary W. Small, Yasar Torres-Yaghi, Fernando Pagan, Marwan Sabbagh

Published in: Neurology and Therapy | Issue 4/2022

Login to get access

Abstract

Introduction

Hallucinations and delusions present with psychosis are debilitating non-motor symptoms of Parkinson’s disease, with a prevalence of up to 50–70% at some point during the course of the disease. Often patients and caregivers do not report the presence of hallucinations or delusions unless specifically questioned. A panel of experts in neurology and geriatric psychiatry convened to develop a simple screening tool and guidance on diagnosis and treatment of Parkinson’s disease psychosis (PDP).

Methods

The working group reviewed literature for existing PDP guidelines on diagnosis and management and identified gaps in recommendations. The group discussed and developed a screening tool and treatment guidance that addressed the gaps in existing methodology based on their clinical experience.

Results

The proposed screening tool consists of two parts: (1) a brief pre-visit screening portion to be completed by the patient and caregiver, and (2) a clinician portion to be completed via clinical interview of the patient and caregiver. If psychotic symptoms are present, an appropriate treatment plan is developed for PDP based on evaluation.

Conclusions

This simple screening tool and treatment guidance offers a practical clinical approach for clinicians in the diagnosis and management of PDP.
Literature
2.
go back to reference Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996–1001.CrossRefPubMed Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996–1001.CrossRefPubMed
3.
go back to reference Levin J, Hasan A, Hoglinger GU. Psychosis in Parkinson’s disease: identification, prevention and treatment. J Neural Transm (Vienna). 2016;123(1):45–50.CrossRefPubMed Levin J, Hasan A, Hoglinger GU. Psychosis in Parkinson’s disease: identification, prevention and treatment. J Neural Transm (Vienna). 2016;123(1):45–50.CrossRefPubMed
4.
go back to reference Taddei RN, Cankaya S, Dhaliwal S, Chaudhuri KR. Management of psychosis in Parkinson’s disease: emphasizing clinical subtypes and pathophysiological mechanisms of the condition. Parkinsons Dis. 2017;2017:3256542.PubMedPubMedCentral Taddei RN, Cankaya S, Dhaliwal S, Chaudhuri KR. Management of psychosis in Parkinson’s disease: emphasizing clinical subtypes and pathophysiological mechanisms of the condition. Parkinsons Dis. 2017;2017:3256542.PubMedPubMedCentral
5.
go back to reference Fenelon G, Soulas T, Zenasni F, Cleret de Langavant L. The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25(6):763–6.CrossRefPubMed Fenelon G, Soulas T, Zenasni F, Cleret de Langavant L. The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25(6):763–6.CrossRefPubMed
7.
go back to reference Cruz MP. Pimavanserin (Nuplazid): a treatment for hallucinations and delusions associated with Parkinson’s disease. P T. 2017;42(6):368–71.PubMedPubMedCentral Cruz MP. Pimavanserin (Nuplazid): a treatment for hallucinations and delusions associated with Parkinson’s disease. P T. 2017;42(6):368–71.PubMedPubMedCentral
9.
go back to reference Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review. Mov Disord. 2019;34(2):180–98.CrossRefPubMedPubMedCentral Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review. Mov Disord. 2019;34(2):180–98.CrossRefPubMedPubMedCentral
10.
go back to reference Divac N, Stojanovic R, Savic Vujovic K, Medic B, Damjanovic A, Prostran M. The efficacy and safety of antipsychotic medications in the treatment of psychosis in patients with Parkinson’s disease. Behav Neurol. 2016;2016:4938154.CrossRefPubMedPubMedCentral Divac N, Stojanovic R, Savic Vujovic K, Medic B, Damjanovic A, Prostran M. The efficacy and safety of antipsychotic medications in the treatment of psychosis in patients with Parkinson’s disease. Behav Neurol. 2016;2016:4938154.CrossRefPubMedPubMedCentral
11.
go back to reference Fixen DR. 2019 AGS Beers Criteria for older adults. Pharm Today. 2019;25(11):42–54.CrossRef Fixen DR. 2019 AGS Beers Criteria for older adults. Pharm Today. 2019;25(11):42–54.CrossRef
12.
go back to reference Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40.CrossRefPubMed Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40.CrossRefPubMed
13.
go back to reference NUPLAZID™ (pimavanserin) [package insert]. San Diego: ACADIA Pharmaceuticals; 2016. NUPLAZID™ (pimavanserin) [package insert]. San Diego: ACADIA Pharmaceuticals; 2016.
14.
go back to reference Ballard CG, Kreitzman DL, Isaacson S, et al. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson’s disease psychosis. Parkinsonism Relat Disord. 2020;77:100–6.CrossRefPubMed Ballard CG, Kreitzman DL, Isaacson S, et al. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson’s disease psychosis. Parkinsonism Relat Disord. 2020;77:100–6.CrossRefPubMed
15.
go back to reference Isaacson SH, Ballard CG, Kreitzman DL, et al. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson’s disease psychosis patients. Parkinsonism Relat Disord. 2021;87:25–31.CrossRefPubMed Isaacson SH, Ballard CG, Kreitzman DL, et al. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson’s disease psychosis patients. Parkinsonism Relat Disord. 2021;87:25–31.CrossRefPubMed
16.
go back to reference Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340(10):757–63.CrossRef Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340(10):757–63.CrossRef
17.
go back to reference Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo-controlled study with open follow-up. J Neurol Neurosurg Psychiatry. 2004;75(5):689–95.CrossRefPubMedPubMedCentral Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo-controlled study with open follow-up. J Neurol Neurosurg Psychiatry. 2004;75(5):689–95.CrossRefPubMedPubMedCentral
18.
go back to reference Desmarais P, Massoud F, Filion J, Nguyen QD, Bajsarowicz P. Quetiapine for psychosis in Parkinson disease and neurodegenerative parkinsonian disorders: a systematic review. J Geriatr Psychiatry Neurol. 2016;29(4):227–36.CrossRefPubMed Desmarais P, Massoud F, Filion J, Nguyen QD, Bajsarowicz P. Quetiapine for psychosis in Parkinson disease and neurodegenerative parkinsonian disorders: a systematic review. J Geriatr Psychiatry Neurol. 2016;29(4):227–36.CrossRefPubMed
20.
go back to reference Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.CrossRefPubMed Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.CrossRefPubMed
21.
go back to reference Chaudhuri KR, Schrag A, Weintraub D, et al. The Movement Disorder Society Nonmotor Rating Scale: initial validation study. Mov Disord. 2020;35(1):116–33.CrossRefPubMed Chaudhuri KR, Schrag A, Weintraub D, et al. The Movement Disorder Society Nonmotor Rating Scale: initial validation study. Mov Disord. 2020;35(1):116–33.CrossRefPubMed
22.
go back to reference Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord. 2007;22(13):1901–11.CrossRefPubMed Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord. 2007;22(13):1901–11.CrossRefPubMed
23.
go back to reference Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord. 2006;21(7):916–23.CrossRefPubMed Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord. 2006;21(7):916–23.CrossRefPubMed
24.
go back to reference Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H. Performance of a shortened scale for assessment of positive symptoms for Parkinson’s disease psychosis. Parkinsonism Relat Disord. 2013;19(3):295–9.CrossRefPubMed Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H. Performance of a shortened scale for assessment of positive symptoms for Parkinson’s disease psychosis. Parkinsonism Relat Disord. 2013;19(3):295–9.CrossRefPubMed
26.
go back to reference Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):996–1002.CrossRefPubMed Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):996–1002.CrossRefPubMed
27.
go back to reference Ballard C, Isaacson S, Mills R, et al. Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis. J Am Med Dir Assoc. 2015;16(10):898.e1-e7.CrossRef Ballard C, Isaacson S, Mills R, et al. Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson disease psychosis. J Am Med Dir Assoc. 2015;16(10):898.e1-e7.CrossRef
28.
go back to reference Shine JM, Mills JMZ, Qiu J, et al. Validation of the psychosis and hallucinations questionnaire in non-demented patients with Parkinson’s disease. Mov Disord Clin Pract. 2015;2(2):175–81.CrossRefPubMedPubMedCentral Shine JM, Mills JMZ, Qiu J, et al. Validation of the psychosis and hallucinations questionnaire in non-demented patients with Parkinson’s disease. Mov Disord Clin Pract. 2015;2(2):175–81.CrossRefPubMedPubMedCentral
29.
go back to reference Brandstaedter D, Spieker S, Ulm G, et al. Development and evaluation of the Parkinson Psychosis Questionnaire: a screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson’s disease. J Neurol. 2005;252(9):1060–6.CrossRefPubMed Brandstaedter D, Spieker S, Ulm G, et al. Development and evaluation of the Parkinson Psychosis Questionnaire: a screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson’s disease. J Neurol. 2005;252(9):1060–6.CrossRefPubMed
30.
go back to reference Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22(8):1061–8.CrossRefPubMed Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22(8):1061–8.CrossRefPubMed
Metadata
Title
Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel
Authors
Rajesh Pahwa
Stuart H. Isaacson
Gary W. Small
Yasar Torres-Yaghi
Fernando Pagan
Marwan Sabbagh
Publication date
29-07-2022
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue 4/2022
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-022-00388-y

Other articles of this Issue 4/2022

Neurology and Therapy 4/2022 Go to the issue